



Helsingborg 4 April 2025

**Press release**

## **Aqilion presents results from study of biomarkers in patients with Eosinophilic esophagitis (EoE) at the Digestive Disease Week conference on May 3-6**

**AQILION AB (publ) AQILION AB (publ) presents results from a study conducted by the Company together with Professor Evan Dellon after the research group's abstract was approved at this year's Digestive Disease Week, May 3-6, in San Diego. The study aims to investigate markers in the blood of patients with Eosinophilic esophagitis (EoE) in order to find new methods to diagnose and follow up treatment in the future.**

The aim of the study was to explore proteins in the blood of EoE patients, with a focus on variability at baseline, change with treatment, and whether pre-treatment plasma proteins can predict how patients respond to topical corticosteroid therapy (tCS). The joint global research efforts to support research on EoE and to better understand the disease over time is important for patients, healthcare and anyone trying to develop new treatments.

Professor Evan Dellon, together with Professor Arjan Breedenord and Dr Luc Biedermann, is part of Aqilion's Scientific Advisory Board with a focus on Aqilion's development of AQ280, a selective JAK1 inhibitor, as a new treatment for EoE. The three members of the Scientific Advisory Board are all three well-known KOLs in EoE and they are involved in both the design of Aqilion's clinical studies and the company's research. Collaborations with the Scientific Advisory Board aim to produce new data that can be presented at scientific conferences and in publications.

Sarah Fredriksson, CEO of Aqilion, comments:

- The more the collected research contributes to understanding EoE and facilitating diagnosis, follow-up and treatment, the more value is added to the patient and the care. We are happy and proud of the collaboration that contributes with new data to research in EoE. The studies also support us in the development of AQ280 and it is strategically important and valuable for the operational activities to follow the latest research findings closely through an in-depth collaboration with our Scientific Advisory Board.

**For more information, please contact:**

Sarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, [sarah.fredriksson@aqilion.com](mailto:sarah.fredriksson@aqilion.com)

### **About Aqilion**

Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience in business development in innovative biotech and pharmaceutical companies, the company's experienced team and Board of Directors have successfully navigated the process from drug discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. [www.aqilion.com](http://www.aqilion.com)